Antares Pharma, Inc. (ATRS)

[Bio_pete]

Methotrexate & Testosterone are widely available & all ATRS is doing is changing the delivery method.

MNTA filed for tentative approval of generic Copaxone Dec/2007 & the FDA still can't make a decision. They also did a lot of upfront work on the manufacturing, quality controls, Phase I studies, etc. This is not a simple drug that any generic company can produce for ATRS.

TEVA has continued to state that new MS drugs are a bigger threat to the Copaxone franchise then generics approval, but that may be CEO speak.

The best scenario for investors is a new partnership announcement for a Copaxone injector once TEVA gains approval. It will be a low blow to investors if TEVA doesn't use ATRS after Wotten's hint that 3 X would make a nice fit.